APA (7th ed.) Citation

Overton, E. T., Richmond, G., Rizzardini, G., Thalme, A., Girard, P., Wong, A., . . . Latham, C. L. (2023). Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clinical Infectious Diseases, 76(9), 1646. https://doi.org/10.1093/cid/ciad020

Chicago Style (17th ed.) Citation

Overton, Edgar T., et al. "Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study." Clinical Infectious Diseases 76, no. 9 (2023): 1646. https://doi.org/10.1093/cid/ciad020.

MLA (9th ed.) Citation

Overton, Edgar T., et al. "Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study." Clinical Infectious Diseases, vol. 76, no. 9, 2023, p. 1646, https://doi.org/10.1093/cid/ciad020.